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Abstract
Background: Neonatal diabetes has not been previously 
studied in Ukraine. We investigated the genetic etiology in 
patients with onset of diabetes during the ﬁrst 9 months 
of life.
Methods: We established a Pediatric Diabetes Register to 
identify patients diagnosed with diabetes before 9 months 
of age. Genetic testing was undertaken for 42 patients with 
permanent or transient diabetes diagnosed within the first 
6 months of life (n = 22) or permanent diabetes diagnosed 
between 6 and 9 months (n = 20).
Results: We determined the genetic etiology in 23 of 42 
(55%) patients; 86% of the patients diagnosed before 
6 months and 20% diagnosed between 6 and 9 months. 
The incidence of neonatal diabetes in Ukraine was calcu­
lated to be 1 in 126,397 live births.
Conclusions: Genetic testing for patients identified 
through the Ukrainian Pediatric Diabetes Register iden­
tified KCNJ11 and ABCC8 mutations as the most common 
cause (52%) of neonatal diabetes. Transfer to sulfonyl­
ureas improved glycemic control in all 11 patients.
Keywords: neonatal diabetes; sulfonylurea; treatment; 
Ukraine.
Introduction
The incidence of diabetes mellitus (DM) in pediatric 
population of Ukraine has greatly increased in recent 
years, especially in children aged from 0 to 6 years (1, 2). 
The Ukrainian Pediatric Diabetes Register was estab­
lished in 2002 and includes 8629 children with type 1 
diabetes, a prevalence of 1 in 925 for the pediatric popu­
lation in 2012.
Over the last decade, it has become clear that not all 
cases of childhood­onset diabetes are autoimmune type 
1 diabetes and patients diagnosed with neonatal diabe­
tes in the first 6  months of life are very likely to have a 
monogenic form of diabetes (3, 4). The key breakthrough 
was the discovery that activating mutations in the KCNJ11 
and ABCC8 genes [encoding the ATP­sensitive potassium 
channel subunit Kir6.2 and the regulatory subunit sulfo­
nylurea receptor 1 (SUR1)] are the most common cause of 
neonatal diabetes (5–7). Most of these patients respond to 
sulfonylurea treatment with an improvement in glycemic 
control (5, 8–12) without hypoglycemia (13–15). Approxi­
mately, 20% of patients have more severe mutations that 
also cause developmental delay. Improvements in motor 
tone and cognition have been reported after transfer to 
sulfonylureas (16).
We established a new neonatal section of the Ukrain­
ian Pediatric Diabetes Registry to identify cases of neona­
tal diabetes for genetic testing. The aim of the study was 
to determine the genetic cause of neonatal diabetes in 
Ukraine and investigate treatment change in patients with 
KCNJ11 or ABCC8 mutations.
Materials and methods
Subjects
A neonatal diabetes section of the Ukrainian Pediatric Diabetes Reg­
istry was created in 2012 to include children diagnosed with diabetes 
before 9  months of age identified by regional Ukrainian pediatric 
endocrinologists. A pediatric neurologist confirmed the presence of 
any abnormal neurological features.
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Genetic testing
Sequencing of the KCNJ11, ABCC8, and INS genes was carried out 
according to previously described methods (5, 17–18). Additional test­
ing for chromosome 6q24 methylation and GLIS3 (19) was performed 
according to the clinical phenotype of the patients. Analysis of the 
chromosome 6q24 locus was undertaken using previously described 
methods to detect duplications, uniparental disomy, and methyla­
tion abnormalities (20, 21). Next­generation sequencing of all known 
neonatal diabetes genes (22) was performed in any child diagnosed 
in the first 6 months of life where a mutation had not been identified.
Statistical analysis
Clinical characteristics are presented as median (range) and compar­
ative statistics predominantly used the Friedman’s test and Fisher’s 
exact test.
Results
Incidence of neonatal diabetes in Ukraine
We identified 46 cases with diabetes diagnosed before 
9 months of age (including 24 cases diagnosed in the first 
6  months of life) from the Ukrainian Pediatric Diabetes 
Register. DNA samples were obtained from 42 patients for 
genetic testing (91.3%). Between January 2012 and Decem­
ber 2014 there were 12 new registered cases with neonatal 
diabetes (diagnosed before 6 months of age) and 1,516,760 
live births, giving an incidence of neonatal diabetes of 1 
in 126,397.
Patients with a genetic diagnosis
Mutations were identified in 19/22 patients (86.4%) diag­
nosed with diabetes in the first 6  months of life (see 
Table  1). Only 4/20 patients (20%) diagnosed between 6 
and 9 months had a mutation. The clinical characteristics 
of all patients with a mutation causing neonatal diabetes 
are shown in Table 2.
KCNJ11 mutations (n = 8 patients)
All eight patients have isolated diabetes: seven were diag­
nosed before 6 months and one at 7.5 months. One patient 
heterozygous for the transient diabetes p.E229K mutation 
is aged 1.5  years but has not entered diabetes remission 
yet. The patients with the p.G53D and p.V59M mutations 
are currently aged 3 and 8  years and show no evidence 
of developmental delay. One patient, who was diagnosed 
with diabetes at 3  months of age, inherited the p.R201H 
KCNJ11 mutation from his/her 29­year­old mother. Analy­
sis of parental samples confirmed that the remaining 
seven probands had de novo mutations. Testing of one 
patient’s unaffected twin brother identified mosaicism in 
his leukocyte DNA at a level of ~10%.
ABCC8 mutations (n = 4 patients)
One patient with transient diabetes was heterozygous for 
a novel p.I585T ABCC8 mutation which was inherited from 
his 23­year­old mother who was diagnosed with “type 2” 
diabetes at 21 years. The proband’s maternal grandfather 
and uncle are also affected (genetic testing was not under­
taken in any relatives).
Three patients had severe developmental delay (two 
siblings with a previously reported heterozygous p.I49F 
mutation) (11) and one patient had compound heterozy­
gous for the previously reported p.V324M mutation (23) 
and a novel p.R1394L mutation.
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Table 1: Genetic causes of neonatal diabetes in patients from the Ukraine Pediatric Diabetes Register. 
Gene   Mutation(s)   Onset before 6 
months, n = 22 
(52.4%)
  Onset between 
6 and 9 months, 
n = 20 (47.6%)
KCNJ11   p.R201C (n = 3), p.R201H (n = 2), p.G53D (n = 1), p.V59M (n = 1), p.E229K (n = 1)   7 (31.8%)  1 (5%)
ABCC8   p.V324M/p.R1394L (compound heterozygous), p.I585T, p.I49F (n = 2)   4 (18.2%)  –
INS   p.C96Y, p.G32S (n = 2), p.L41P   1 (4.5%)  3 (15%)
EIF2AK3   p.E419fs/p.G1010V (compound heterozygous), p.G1010V/p.G1010V (homozygous)   2 (9.1%)  –
GLIS3   p.P444fs/p.H647R   1 (4.5%)  –
Chr6q24   Paternal uniparental isodisomy   3 (13.7%)  –
GCK   p.E395X   1 (4.5%)  –
No mutation    3 (13.7%)  16 (80%)
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The parents of the two siblings with the p.I49F muta­
tion are unaffected and the mutation was not detected in 
either parent’s leukocyte DNA in keeping with germline 
mosaicism. Both children have a severe form of devel­
opmental delay, epilepsy, and neonatal diabetes (DEND) 
syndrome. The proband was diagnosed with diabetes at 
3 months which remitted at the age of 1 year and relapsed 
at 2  years 3  months after starting hypothyroidism treat­
ment. At age 2 years, the proband had a severe general­
ized hypotonia, with no visual contact, no babbling, 
psychomotor retardation, epilepsy, and severe physical 
delay [height: 75 cm ( < 3rd centile), weight: 6000 g ( < 3rd 
centile)]. His sister at age 5  months developed convul­
sions and hypoglycemic coma, and at age 6 months devel­
oped neonatal diabetes and received insulin for only few 
days. At 18 months, she was noted to have psychomotor 
retardation (severely hypotonic, no babbling, poor visual 
contact) and growth delay (height: 75  cm [ < 3rd centile], 
weight: 8100 g [ < 3rd centile]).
The patient with the compound heterozygous ABCC8 
mutation had inherited the p.V324M mutation from the 
father and the novel p.R1394L mutation from the mother. 
This child has severe iDEND syndrome but no epilepsy. At 
7 years of age, he has a severe generalized hypotonia and 
is unable to sit, hold his head upright, walk or talk.
INS mutations (n = 4 patients)
These included one patient diagnosed with diabetes at 
4 months with a de novo p.C96Y INS mutation and three 
patients diagnosed between 6 and 9 months (p.L41P and 
p.G32S n = 2). In one case, p.G32S was inherited from the 
unaffected father whose mutation level in leukocyte DNA 
is ~15%. Interestingly, the child’s diabetes had remitted 
for 2  months from the age of 8 months. Another child 
diagnosed at 8  months with a de novo p.G32S mutation 
is obese (BMI 19.8 kg/m²,  > 95 p.c.) at the age of 6 years. 
Adding metformin (850 mg/day) to insulin treatment has 
improved glycemic control with HbA1c reduction from 90 to 
70 mmol/mol (10.4%–8.6%), respectively, after 3 months 
and without any change in insulin dose.
EIF2AK3 (n = 2 patients)
One patient was diagnosed with diabetes at the age of 3 
months. Sanger sequencing of the ABCC8 gene identi­
fied a novel, maternally inherited, heterozygous variant 
of uncertain significance, p.P201L (c.602C > T). A trial 
with sulfonylurea was started, but no durable response 
was achieved. Further genetic testing of all known neo­
natal genes by next­generation sequencing identified 
compound heterozygous EIF2AK3 mutations, p.E419fs 
and p.G1010V. At age 3 years the child does not have addi­
tional features of Wolcott­Rallison syndrome besides mild 
growth retardation. Targeted next­generation sequenc­
ing in a 2nd patient born to consanguineous parents 
demonstrated homozygosity for the same novel EIF2AK3 
p.G1010V mutation. The child is currently 8 months of age 
and does not have other features of Wolcott­Rallison syn­
drome. Identification of the same novel mutation in two 
probands raises the possibility that p.G1010V is a founder 
mutation.
GLIS3 mutations (n = 1 patient)
This patient presented in the 1st week of life with dia­
betic ketoacidosis (glucose  > 20 mmol/L) and has con­
genital hypothyroidism, patent foramen ovale with left 
ventricle distention and polycystic kidneys. The patient 
is compound heterozygous for two GLIS3 mutations, 
p.P444fsdelG and p.H647R (19).
Chromosome 6q24 abnormalities 
(n = 3 patients)
All three patients have paternal uniparental isodisomy. 
Two had intrauterine growth retardation, macroglossia, 
anemia, and patent foramen ovale.
GCK (n = 1 patient)
The child had mild fasting hyperglycemia (FBG at 5 months 
6.1 mmol/L, at 8  months 7.4 mmol/L). Her mother was 
diagnosed with gestational diabetes at 19 years of age and 
there is a family history of diabetes affecting the maternal 
grandparents. A heterozygous GCK mutation, p.E395X, 
was identified in both the mother and child. Neither are 
receiving pharmaceutical treatment.
Transfer to sulfonylurea therapy for patients 
with KCNJ11/ABCC8 mutations
The transfer was performed according to the proto­
col devised by Hattersley et  al. (24) but with three to 
five daily doses (later reducing to two to three doses) 
and omission of fast­acting insulin from the outset. 
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Infants generally needed more frequent doses than 
those who transferred later. A total of 11 patients with 
KCNJ11 and ABCC8 mutations were able to stop insulin 
and achieve glycemic control with sulfonylurea (glib­
enclamide). After 3  months of sulfonylurea treatment, 
the median HbA1c level decreased from 57 (49–81) to 42 
(37–47) mmol/mol [7.4 (6.6–9.6)–6.0 (5.5–6.5)%). After 
1 year of sulfonylurea treatment all children had HbA1c 
level  < 48  mmol/mol ( < 6.5%), the median HbA1c level 
was 38 (36–41) mmol/mol [5.6 (5.4–5.9)%], p = 0.016 (see 
Table 3, Figure 1).
The patient with severe DEND syndrome caused by 
the compound heterozygous ABCC8 mutations p.V324M 
and p.R1394L showed no neurological improvement 
after  2  years on sulfonylurea treatment (current dose 
0.15 mg/kg/day).
Sulfonylurea treatment was initiated in the boy with 
the p.I49F ABCC8 mutation when his diabetes relapsed 
aged 2 years 3 months. The initial dose of 0.07 mg/kg/day 
was increased to 0.2  mg/kg/day after starting treatment 
with growth hormone (0.025 mg/kg/day). His sister has 
been treated with low­dose sulfonylurea (0.06 mg/kg/day) 
for a year.
Discussion
Establishing a neonatal diabetes section of the Ukrainian 
Pediatric Diabetes Register has facilitated the identifica­
tion of cases for genetic testing and provided an estimate 
of the incidence.
Table 3: Sulfonylurea transfer in 11 patients with KCNJ11/ABCC8 gene mutationsa. 
Patient   Gene   Mutation   Age at 
transfer
  Starting dose, 
mg/kg/day
  Maximum 
dose,  
mg/kg/day
  Dose after 
3 months, 
mg/kg/day
  HbA1c 
pre-transfer, 
mmol/mol
  HbA1c 
3 months later, 
mmol/mol
  Side 
effects
  Neurological 
improvement  
(N/A if no 
features)
1   KCNJ11   p.R201C   62 months  0.1   1.1   0.58   54  45  No   NA
2   KCNJ11   p.R201C   6 months   0.1   0.7   0.32   81  48  No   NA
3   KCNJ11   p.R201C   4 months   0.1   0.2   0.15   148  37  No   NA
4   KCNJ11   p.R201H   1 month   0.1   0.25   0.18   128  27  No   NA
5   KCNJ11   p.R201H   28 years   5 mg/day   15 mg/day   15 mg/day   65  57  No   NA
6   KCNJ11   p.G53D   20 months  0.1   0.75   0.75   47  42  No   NA
7   KCNJ11   p.V59M   72 months  0.1   1.0   0.68   54  41  No   NA
8   KCNJ11   p.E229K   16 months  0.05   0.1   0.075   49  43  No   NA
9   ABCC8   p.I49F   25 months  0.05   0.1   0.1   41  42  No   No
10   ABCC8   p.I49F   6 months   0.05   0.07   0.07   57  48  No   No
11   ABCC8   p.V324M/
p.R1394L
  57 months  0.1   1.0   0.54   61  32  No   No
aPatient 12 with the p.I585T ABCC8 mutation entered remission before initiation of sulphonylurea therapy.
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Figure 1: HbA1c (mmol/mol) before 3 months and 1 year after 
sulfonylurea treatment (p = 0.016). The daily dose of sulfonylurea 
decreased from 0.48 (0.09–0.75) to 0.32 (0.1–0.59) and 0.16 
(0.12–0.28) mg/kg/day after 3 months and 1 year of treatment 
accordingly, p > 0.05. No side effects were reported.
Incidence of neonatal diabetes in Ukraine
The incidence of neonatal diabetes in Ukraine over a 
36­month period (2012–2014) was 1 in 126,397. This figure is 
similar to studies from Germany [1 in 89,000 (25)] and Italy 
[1:90,000 (26)]. As permanent diabetes (PNDM) accounts 
for ~50% of neonatal diabetes cases, our incidence is also 
consistent with reports of PNDM in the UK, the Nether­
lands, and Poland, of at least 1 in 260,000 live births (27), 
1 in 210,000 in Italy (28), and 1 in 214,000 live births from 
the Slovakian diabetes register (29). The highest incidence 
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of permanent neonatal diabetes is observed in countries 
with high rates of consanguinity [1 in 21,196 (30)].
Sulfonylurea transfer in patients with KCNJ11 
and ABCC8 mutations
KATP channel gene mutations were the leading cause of 
neonatal diabetes (52.2%). Transfer from insulin to sulfo­
nylurea was successful in all 11 patients with these muta­
tions with improved glycemic control within 3 months and 
HbA1c levels below  < 48 mmol/mol ( < 6.5%) after 1 year. 
The patients with the p.G53D and p.V59M KCNJ11 muta­
tions are currently aged 3 and 8 years. They have been 
treated with high­dose sulfonylureas ( > 0.5 mg/kg/day) and 
show no evidence of the mild to moderate developmental 
delay observed in other patients with these mutations (10, 
31–34). In contrast, three patients with ABCC8 mutations 
(p.I49F in two siblings and one case compound heterozy­
gous for p.V324M and p.R1394L) have severe developmental 
delay. The siblings with the p.I49F mutation were trans­
ferred to low­dose sulfonylurea therapy (  ≤  0.1 mg/kg/day) 
because of the transient nature of their diabetes. A spike of 
blood glucose 1 h after eating was observed in two patients 
(with KCNJ11 p.R201C and the ABCC8 mutations p.V324M 
and p.R1394L). This was solved by increasing the interval of 
sulfonylurea uptake up to 50 minutes pre meals. 
Other genetic causes of neonatal diabetes 
in Ukraine
We identified three cases of transient neonatal diabetes 
due to chromosome 6q24 uniparental isodisomy and eight 
patients with mutations in non­KATP channel genes. These 
included four patients with heterozygous INS mutations 
and one patient where sequence analysis of the GLIS3 
gene was indicated by his hypothyroidism and polycys­
tic kidneys. For three patients, the genetic analysis was 
achieved through testing all the known neonatal diabe­
tes genes by targeted next­generation sequencing (22). 
Two probands were diagnosed with Wolcott­Rallison syn­
drome but have not yet developed the extra­pancreatic 
features. One patient with mild fasting hyperglycemia has 
a heterozygous GCK mutation.
Cut-off age for genetic testing to identify 
patients with neonatal diabetes
In this study, we performed genetic testing for any patient 
diagnosed with diabetes before 9  months and identified 
a genetic etiology in four cases diagnosed after 6 months 
(7.3–8.0 months), the usual definition of neonatal diabetes. 
Three probands had an INS mutation and one individual 
was heterozygous for a KCNJ11 mutation. This patient was 
able to transfer from daily insulin injections to sulfonylu­
rea tablets resulting in improved glycemic control [HbA1c: 
47 mmol/mol (pre­transfer) vs. 42 mmol/mol (3  months 
post­transfer)]. Consistent with our earlier study, the 
pick­up rate for mutations was significantly lower in 
patients diagnosed after 6  months compared to those 
diagnosed before 6 months (20% vs. 86%; p  ≤  0.0001) (35). 
The benefits of a genetic diagnosis, in terms of improving 
medical management and quality of life for those with 
KATP channel mutations as well as providing an accurate 
recurrence risk, highlights the utility of testing all patients 
diagnosed up to 9 months of age.
In conclusion, Ukraine has a similar incidence of 
neonatal diabetes as other European countries and KATP 
channel gene mutations are the most common cause. 
All patients with KCNJ11 and ABCC8 mutations were suc­
cessfully switched from insulin injections to oral sulfo­
nylurea therapy with an improvement in their glycemic 
control. Targeted next­generation sequencing technology 
increased the number of patients with a confirmed genetic 
etiology of neonatal diabetes and provides an accurate 
recurrence risk for the families. The identification of a 
KCNJ11 mutation in a patient diagnosed at 7.5  months 
highlights the importance of providing genetic testing to 
those diagnosed between 6 and 9 months.
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